🔬 The merger combines SERVA’s electrophoresis technologies with LICORbio’s imaging platforms.
📈 This integration aims to provide seamless workflows from sample preparation to analysis.
🏢 Serva’s Heidelberg location will remain operational post-acquisition.
🤝 The move aligns with LICORbio’s focus on meeting research community needs.
Introduction:
The article discusses the recent acquisition of Serva Electrophoresis by LICORbio, a prominent move aimed at enhancing LICORbio’s offerings in the field of protein analysis. This transaction highlights the company’s strategic focus on integrating advanced technologies to improve research capabilities for scientists working in protein, DNA, and RNA analysis.
- LICORbio has acquired Serva Electrophoresis, a company known for its electrophoresis reagents and consumables, thereby expanding its market position.
- The acquisition will integrate SERVA’s technologies with LICORbio’s imaging platforms, providing comprehensive workflow solutions from sample preparation to data quantification.
- Tom Reslewic, CEO of LICORbio, stated that this move aligns with the company’s strategic aim to remain responsive to the evolving needs of the research community.
- The acquisition is effective immediately, with plans to maintain Serva’s existing operations in Heidelberg.
- This integration is expected to facilitate more accurate and efficient analysis workflows in protein, DNA, and RNA studies.
Conclusion:
The acquisition of Serva Electrophoresis by LICORbio signifies a strategic enhancement of its technological capabilities in protein analysis. By merging Serva’s specialized products with its established imaging tools, LICORbio aims to provide a more effective and integrated solution for researchers. This transaction not only underscores LICORbio’s commitment to addressing research needs but also positions the company for future growth and innovation in the biotechnology sector.
